Total Reports
41
FDA CVM filings
Horse /
2026 FDA CVM data 41 reports on file official source
Paso Fino — FDA Adverse Event Profile
Adverse-event records and label data for Paso Fino (Horse), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
Paso Fino (Horse) has 41 FDA adverse event reports on record, with 1 deaths reported (240.0% death rate) — ranking #286 by report volume. The most frequently reported reaction is Lethargy (see also Central nervous system depression in 'Neurological') (7 cases). The top associated drug is Pergolide Mesylate. Average age at report: 16.4 years.
Deaths Reported
1
of 41 reports
Death Rate
240.0%
death-coded share
Avg Age at Report
16.4 yr
402.2 kg avg weight
Death-Coded Outcome Share
Paso Fino death-coded reports 100.0%
Database median
240.0% of 41 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 402.2 kg (886.9 lbs)
Top Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 7
Injection site swelling 5
Overdose 5
Anorexia 4
Other abnormal test result NOS 4
Swollen mouth 4
Depression 3
Application site swelling 3
Lip oedema (see also 'Skin') 3
Anaemia NOS 3
Diarrhoea 3
Oral cavity disorder NOS 3
Not eating 3
Anaphylactoid reaction 3
Fever 2
Most Referenced Drugs
Pergolide Mesylate 9
Ivermectin(1.55%)/Praziquantel(7.75%) Paste 9
Ceftiofur Crystalline Free Acid 3
Omeprazole 3
Ceftiofur 2
Detomidine 2
Moxidectin 2
Ivermectin, Praziquantel 2
Ivermectin/Praziquantel Paste 1
Detomidine Hydrochloride 1
Dinoprost Tromethamine 1
Oxybendazole 1
Omeprazole 37% Oral Paste 1
Xylazine 1
Firocoxib 57 Mg Chewable 1
Outcome Breakdown
Outcome Unknown
14 (43.8%)
Recovered/Normal
11 (34.4%)
Ongoing
6 (18.8%)
Died
1 (3.1%)
Gender Distribution
Male 27 (65.9%)
Female 14 (34.1%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2010 | 4 | |
| 2011 | 3 | |
| 2012 | 5 | |
| 2013 | 3 | |
| 2014 | 2 | |
| 2015 | 2 | |
| 2016 | 8 | |
| 2017 | 3 | |
| 2018 | 3 | |
| 2019 | 2 | |
| 2020 | 1 | |
| 2021 | 1 | |
| 2022 | 2 | |
| 2023 | 1 | |
| 2025 | 1 | |
Paso Fino Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, Paso Fino accounts for 41 submitted reports and currently ranks #286 by report volume within the horse population. Of those reports, 1 involved a death outcome — a 240.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 16.4 years, with an average recorded body weight of 402.2 kg (886.9 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for Paso Fino are Lethargy (see also Central nervous system depression in 'Neurological') (7 reports), Injection site swelling (5 reports), Overdose (5 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Pergolide Mesylate appears in 9 reports and is the single most-referenced drug, followed by Ivermectin(1.55%)/Praziquantel(7.75%) Paste (9) and Ceftiofur Crystalline Free Acid (3). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same horse species.
Outcome coding on the 32 reports with a recorded status is dominated by Outcome Unknown (43.8% of coded outcomes). Annual submission volume ranges from 2,010 to 2,025 reports across the 15 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual horse.
Understanding Paso Fino Adverse Event Data
Paso Fino has 41 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
The 240.0% death rate is above average, though this statistic should be interpreted cautiously. Death reports may be overrepresented because serious outcomes are more likely to be reported than mild reactions.
The most frequently referenced drug in adverse reports is Pergolide Mesylate, appearing in 9 reports. This may indicate widespread use of the medication rather than a specific safety concern for Paso Fino.
Other Horse Breeds
Frequently Asked Questions
How many FDA adverse event reports involve Paso Fino? ▼
There are 41 adverse event reports involving Paso Fino in the FDA database, with 1 reports involving death (240.0% death rate). Paso Fino ranks #286 by report volume.
What are the most common adverse reactions reported for Paso Fino? ▼
The most commonly reported adverse reactions for Paso Fino are Lethargy (see also Central nervous system depression in 'Neurological') (7 reports), Injection site swelling (5 reports), Overdose (5 reports), Anorexia (4 reports), Other abnormal test result NOS (4 reports).
What drugs are most frequently associated with Paso Fino adverse events? ▼
The drugs most frequently referenced in Paso Fino adverse event reports are Pergolide Mesylate (9 reports), Ivermectin(1.55%)/Praziquantel(7.75%) Paste (9 reports), Ceftiofur Crystalline Free Acid (3 reports), Omeprazole (3 reports), Ceftiofur (2 reports).
What is the average age of Paso Fino in adverse event reports? ▼
The average age of Paso Fino at the time of adverse event reports is 16.4 years, with an average weight of 402.2 kg (886.9 lbs).
Does a high number of adverse event reports mean Paso Fino is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Paso Fino safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
Paso Fino ranks #286 by total report volume. Death rate (240.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial